Patient rated outcomes and survivorship following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CS+HIPEC)†

UNCG Author/Contributor (non-UNCG co-authors, if there are any, appear on document)
Craig S. Cashwell, Professor (Creator)
The University of North Carolina at Greensboro (UNCG )
Web Site:

Abstract: Background Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CS+HIPEC) is a treatment combining cytoreductive surgery with hyperthermic chemotherapy directly into the peritoneal cavity. Recipients may gain extended life when compared with best supportive care; yet results often are achieved with substantial morbidity and health-related quality of life (HRQOL) deficits. The purpose of this study was to record patient rated outcomes and the HRQOL of long-term survivors.MethodsOne hundred and two patients living 12+ months post-treatment completed a survey including the Medical Outcomes Study 36-item Short Form Health Survey (SF-36), Functional Assessment of Cancer Therapy-Colon (FACT-C), and Pittsburgh Sleep Quality Index.ResultsSF-36 Physical Component scores were significantly lower than general population norms (46.7, z?=?-2.943, P?=?0.003), while Mental Component scores were significantly higher (53.6, z?=?4.208, P?=?0.001). FACT scores were higher than general FACT normative scores. The majority (56%) of these survivors reported significant sleep quality impairment.Conclusion Although most HRQOL scores were comparable to or higher than those of the general population, long-term physical and functional deficits remain. These deficits, along with the poor sleep quality of recipients, may be improved by survivorship programs or targeted psychosocial interventions. J. Surg. Oncol. 2012; 106:376–380. © 2012 Wiley Periodicals, Inc.

Additional Information

Journal of Surgical Oncology
Language: English
Date: 2012
health-related quality of life, peritoneal carcinomatosis, long-term survivorship

Email this document to